You have read all your free articles, to continue reading subscribe to read the rest of this content.
Genmab has entered an agreement to grant Gilead Sciences, an exclusive license and an option on a second exclusive license, to use the DuoBody technology platform to create and develop bispecific antibody candidates for a therapeutic program targeting HIV. Under the terms of the agreement, GenmabAlready a subscriber Login You…
Genmab and Seagen have announced the submission of a Biologics License Application (BLA) to the FDA seeking accelerated approval for tisotumab vedotin. This BLA requests FDA approval of tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progrAlready a subscriber Login You have read…
AstraZeneca and MSD have announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the MEK 1/2 inhibitor and potential new medicine selumetinib. This designation is for the treatment of paediatric patients aged three years and older with neuroAlready a subscriber Login You have…
UK's Sygnature Discovery will collaborate with Swedish biotech company Pelago Bioscience to provide target engagement assays with Pelago’s patented Cellular Thermal Shift Assay (CETSA) method. Pelago’s CETSA method enables measurements to be made within cellular systems. For the first time reAlready a subscriber Login You have read all your free…
